GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Intangible Assets

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Intangible Assets : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Brainstorm Cell Therapeutics's intangible assets for the quarter that ended in Dec. 2023 was $0.00 Mil.


Brainstorm Cell Therapeutics Intangible Assets Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Intangible Assets Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Brainstorm Cell Therapeutics  (NAS:BCLI) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Brainstorm Cell Therapeutics Intangible Assets Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Executives
Stacy Lindborg officer: EVP, Head Global Clin Research C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor director BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor officer: Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits officer: Chief Executive Officer 110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun officer: EVP and COO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd. other: Member of 10% owner group MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi director 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel director 188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya officer: Chief Commercial Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah officer: EVP, CFO and Treasurer C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel director 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Headlines

From GuruFocus